Alumis Inc. ALMS
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- -59.43%
- 1 year
- -42.77%
5D -1.64 (-27.47%)
- Market cap
- 514.09M
- Revenue (ttm)
- 7.40M
- EPS (ttm)
- -3.53
- Shares out
- 129.44M
- Forward P/E
- -2.82
- YTD return
- -59.43%
- 1-year return
- -42.77%
- 50-day average
- 21.50
- 200-day average
- 22.28
- Volume
- 1.79M
- Avg volume
- 2.86M
- Open
- 4.24
- Previous close
- 4.33
- Day's range
- 3.94 – 4.36
- 52-week range
- 3.96 – 30.30
- Beta
- -0.79
- Analysts
- Strong Buy
- Price target
- 32.13 (+711.2%)
Key statistics
- Enterprise value
- 556.67M
- Price / sales
- 141.89
- Price / book
- 2.30
- Revenue growth
- -37.70%
- Free cash flow
- -208.64M
- Total cash
- 502.29M
- Total debt
- 36.43M
- Return on equity
- -93.65%
- Short % of float
- 7.27%
Fundamental scorecard
3 of 25 checks passed on ALMS’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.73 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.767 | -1.11 | -0.34 | -44.72% |
| May 14, 2026 | Mar 31, 2026 | -0.74273 | -0.74 | 0.00 | +0.37% |
| Mar 19, 2026 | Dec 31, 2025 | -0.97 | -0.95 | +0.02 | +2.06% |
| Nov 13, 2025 | Sep 30, 2025 | -0.92 | -1.06 | -0.14 | -15.22% |
| Aug 13, 2025 | Jun 30, 2025 | -1.11 | -1.17 | -0.06 | -5.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 2026 | Guggenheim | down | Buy | Neutral |
| Sep 2, 2026 | Oppenheimer | main | Outperform | Outperform |
| Sep 2, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 2, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 2, 2026 | HC Wainwright & Co. | up | Neutral | Buy |
| Aug 14, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alumis.com
News
Your note
Sign in to keep a note on ALMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Purchase | Sep 7, 2026 | 0 |
| AYURMAYA CAPITAL MANAGEMENT COMPANY, LP | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 20, 2025 | 0 |
| BABLER MARTIN | Chief Executive Officer | Purchase | Mar 31, 2025 | 0 |
| BRADLEY MARK CHRISTOPHER | Officer | Sale | Aug 2, 2026 | 88,585 |
| DRAPPA JORN | Officer | Sale | Aug 2, 2026 | 56,892 |
| FORESITE CAPITAL MANAGEMENT VI, LLC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 7, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ayurmaya Capital Management Company, LP | 11.70% | 15,139,707 | 122.78M | Jun 29, 2026 |
| Blackrock Inc. | 6.35% | 8,218,151 | 66.65M | Jun 29, 2026 |
| FMR, LLC | 5.23% | 6,769,170 | 54.90M | Jun 29, 2026 |
| Deep Track Capital, Lp | 4.90% | 6,348,558 | 51.49M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 4.90% | 6,345,219 | 51.46M | Jun 29, 2026 |
| Foresite Capital Management V, LLC | 4.56% | 5,896,995 | 47.82M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.43% | 3,139,756 | 25.46M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.55% | 2,012,064 | 16.32M | Jul 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.06% | 1,369,916 | 11.11M | Jun 29, 2026 |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 0.84% | 1,088,300 | 8.83M | Jun 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 0.77% | 999,800 | 8.11M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.75% | 977,098 | 7.92M | Jun 29, 2026 |
